Pharma
-
Q&A
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
What happened to ivermectin?
The saga of the anti-parasitic drug continues.
By Alexandra Pecci • Sept. 20, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
PBMs, PhRMA trade blame over drug costs in House hearing
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second PBM hearing on Tuesday.
By Rebecca Pifer • Sept. 19, 2023 -
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
By Kelly Bilodeau • Sept. 18, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023 -
A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say
A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.
By Alexandra Pecci • Sept. 12, 2023 -
In advocates’ ongoing push for superbug funding, ‘$6 billion is nothing’
The PASTEUR Act is likely heading for another legislative blow, but advocates say they see a future for the mechanism to fund the battle against antimicrobial resistance.
By Karissa Waddick • Sept. 8, 2023 -
Profile
‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.
By Michael Gibney • Sept. 7, 2023 -
Pharma faces a slew of leadership shakeups
Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.
By Karissa Waddick • Sept. 7, 2023 -
Profile
Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery
Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.
By Alexandra Pecci • Sept. 6, 2023 -
Hope sputters for emerging anti-TIGIT drug class
Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.
By Kelly Bilodeau • Sept. 5, 2023 -
Roz Brewer announces sudden departure as CEO of Walgreens
The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.
By Meagan Parrish • Sept. 1, 2023 -
Lawmakers are already gunning for more dramatic drug pricing reforms
Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.
By Karissa Waddick • Aug. 31, 2023 -
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
By Michael Gibney • Aug. 30, 2023 -
Medicare named the first 10 drugs up for negotiation. Now what?
The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.
By Karissa Waddick • Aug. 30, 2023 -
5 of the best places to work in pharma, according to employees
Work-life balance is one major common denominator among the top-ranked pharma employers on Glassdoor.
By Alexandra Pecci • Aug. 29, 2023 -
Are weight loss drugs a win for the global economy?
As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market.
By Karissa Waddick • Aug. 28, 2023 -
Why pharma isn’t done tackling migraines
In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options.
By Kelly Bilodeau • Aug. 28, 2023 -
Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’
FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages.
By Karissa Waddick • Aug. 25, 2023 -
‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax
New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.
By Michael Gibney • Aug. 24, 2023 -
How an AstraZeneca exec is leading the charge in the next immuno-oncology era
The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.
By Michael Gibney • Aug. 17, 2023 -
Q&A
A leading Democrat reveals how his mental health struggles shape his policy approach
Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.
By Karissa Waddick • Aug. 17, 2023